KODIAK SCIENCES INC. Payments to Acquire Marketable Securities
KODIAK SCIENCES INC. (KOD) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-31
- KODIAK SCIENCES INC. payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00.
- KODIAK SCIENCES INC. payments to acquire marketable securities for the quarter ending 2024-09-30 was $0.00.
- KODIAK SCIENCES INC. payments to acquire marketable securities for the quarter ending 2024-06-30 was $0.00.
- KODIAK SCIENCES INC. payments to acquire marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- KODIAK SCIENCES INC. payments to acquire marketable securities for fiscal 2025 was $0.00.
- KODIAK SCIENCES INC. payments to acquire marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- KODIAK SCIENCES INC. payments to acquire marketable securities for fiscal 2023 was $49.35M, a 88.46% decline from fiscal 2022.
- KODIAK SCIENCES INC. payments to acquire marketable securities for fiscal 2022 was $427.77M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $49.35M 10-K · filed 2026-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $49.35M 10-Q · filed 2024-11-14 | $49.35M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $49.35M 10-Q · filed 2024-08-14 | $49.35M derived: sum of 3 quarters · filed 2025-03-27 | $49.35M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | $49.35M 10-Q · filed 2024-05-15 | $49.35M derived: sum of 2 quarters · filed 2025-03-27 | $49.35M derived: sum of 3 quarters · filed 2025-03-27 | $477.11M derived: sum of 4 quarters · filed 2025-03-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $427.77M derived: sum of 3 quarters · filed 2025-03-27 | $427.77M 10-K · filed 2025-03-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $427.77M derived: sum of 2 quarters · filed 2023-11-14 | $427.77M 10-Q · filed 2023-11-14 | $427.77M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $427.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $427.77M 10-Q · filed 2023-08-14 | $427.77M derived: sum of 3 quarters · filed 2024-03-28 | $427.77M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $0.00 derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $0.00 derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $0.00 derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $86.32M 10-K · filed 2023-03-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $86.32M 10-Q · filed 2021-11-09 | $197.05M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $86.32M 10-Q · filed 2021-08-09 | $197.05M derived: sum of 3 quarters · filed 2022-03-01 | $202.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $86.32M 10-Q · filed 2021-05-10 | $197.05M derived: sum of 2 quarters · filed 2022-03-01 | $202.21M derived: sum of 3 quarters · filed 2022-03-01 | $213.41M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $110.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $115.89M derived: sum of 2 quarters · filed 2022-03-01 | $127.10M derived: sum of 3 quarters · filed 2022-03-01 | $150.96M 10-K · filed 2022-03-01 |
| 2019-09-30 | $5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $16.37M derived: sum of 2 quarters · filed 2020-11-09 | $40.23M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $11.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $35.07M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $23.86M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |